AstraZeneca to Purchase Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to purchase Gracell Biotechnologies for a transaction worth of $1.2 billion, as a part of the previous’s efforts to develop its cell therapies enterprise.

The upfront money portion of the deal is $1.Zero billion, a 62.0% premium to Gracell’s final closing value for its American depository shares of $6.19, AstraZeneca stated in an announcement Tuesday.